BridgeBio Pharma, Inc.
BBIO
$34.85
-$0.97-2.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 116.63M | 5.88M | 2.73M | 2.17M | 211.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.63M | 5.88M | 2.73M | 2.17M | 211.12M |
| Cost of Revenue | 2.64M | 2.08M | 598.00K | 598.00K | 598.00K |
| Gross Profit | 113.99M | 3.80M | 2.13M | 1.57M | 210.52M |
| SG&A Expenses | 106.37M | 94.78M | 68.82M | 59.52M | 65.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 220.44M | 227.22M | 189.86M | 174.82M | 207.38M |
| Operating Income | -103.80M | -221.33M | -187.13M | -172.65M | 3.74M |
| Income Before Tax | -169.61M | -266.24M | -164.25M | -75.54M | -36.16M |
| Income Tax Expenses | -- | 1.15M | -- | -- | -- |
| Earnings from Continuing Operations | -169.61M | -267.39M | -164.25M | -75.54M | -36.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.19M | 2.34M | 2.21M | 2.09M | 944.00K |
| Net Income | -167.42M | -265.05M | -162.04M | -73.46M | -35.22M |
| EBIT | -103.80M | -221.33M | -187.13M | -172.65M | 3.74M |
| EBITDA | -102.52M | -219.97M | -185.59M | -171.07M | 5.34M |
| EPS Basic | -0.88 | -1.40 | -0.86 | -0.39 | -0.20 |
| Normalized Basic EPS | -0.47 | -0.85 | -0.69 | -0.65 | -0.04 |
| EPS Diluted | -0.88 | -1.40 | -0.86 | -0.39 | -0.20 |
| Normalized Diluted EPS | -0.47 | -0.85 | -0.69 | -0.65 | -0.04 |
| Average Basic Shares Outstanding | 190.15M | 189.44M | 188.51M | 187.59M | 178.71M |
| Average Diluted Shares Outstanding | 190.15M | 189.44M | 188.51M | 187.59M | 178.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |